ELISA Kit for Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2) Homo sapiens (Human) Antibody ELISA

ACEH; ACEII; ACE-II; Peptidyl-Dipeptidase A; ACE-related carboxypeptidase; Angiotensin-converting enzyme homolog; Metalloprotease MPROT15

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • ELISA Kit for Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2) Packages (Simulation)
  • ELISA Kit for Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2) Packages (Simulation)
  • ELISA Kit for Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2) Results demonstration
  • AEB886Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2) and the recovery rates were calculated by comparing the measured value to the expected amount of Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 82-101 95
EDTA plasma(n=5) 86-103 89
heparin plasma(n=5) 79-94 84

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 80-90% 96-103% 97-104% 94-101%
EDTA plasma(n=5) 94-101% 79-97% 80-102% 93-104%
heparin plasma(n=5) 80-88% 91-98% 80-104% 80-99%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 5 times;
5. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
6. Add 50µL Stop Solution. Read at 450nm immediately.

ELISA Kit for Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2)

Test principle

The microtiter plate provided in this kit has been pre-coated with an antigen. Standards or samples are then added to the appropriate microtiter plate wells with a Horseradish Peroxidase (HRP)-conjugated secondary antibody. After TMB substrate solution is added, those wells that contain Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2) will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Anti-Angiotensin I Converting Enzyme 2 Antibody (Anti-ACE2) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Citations

  • Angiotensin-Converting Enzyme 2 Overexpression Remarkably Ameliorated Glomerular Injury in a Rat Model of Diabetic Nephropathy: A Comparison with ACE InhibitionMolMed: 10_11_liu
  • Plasma Levels of Angiotensin-Converting Enzymes 1 and 2 and AGTR2 (T1247G and A5235G) Gene Polymorphisms Are Associated to Breast Cancer Progression.Scirp: Source
  • ACE2 activation by xanthenone prevents leptin-induced increases in blood pressure and proteinuria during pregnancy in Sprague-Dawley ratsPubmed:25205467
  • Angiotensin converting enzymes in patients with acute respiratory distress syndromeContent: 3
  • Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosisS0021967317311858
  • Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites.pubmed:28895159
  • Lipoxin A attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axisPubmed:29969931
  • Impact of angiotensin-converting enzyme 2 levels on postoperative pneumonia after esophagectomyPubmed:29506841
  • Could cardioprotective effect of ACE2 activator “diminazene aceturate” is more potent than ACE inhibitor “Enalapril” on acute myocardial infarction in rats?Pubmed: 30840489
  • Angiotensin-converting enzymes in acute respiratory distress syndrome
  • AVE 0991 Attenuates Pyroptosis and Liver Damage after Heatstroke by Inhibiting the ROS-NLRP3 Inflammatory Signalling Pathway
  • Relationship between circulating levels of angiotensin-converting enzyme 2-angiotensin-(1–7)-MAS axis and coronary heart diseasePubmed: 31359146
  • Alteration and association between serum ACE2/angiotensin (1-7)/Mas axis and oxidative stress in chronic kidney disease: A pilot studyPubmed: 32756181
  • Equilibrium Angiotensin Metabolite Profiling in Patients with Acute Respiratory Distress Syndrome Indicates Angiotensin Converting Enzyme InhibitionPubmed: 32628511
  • Determinants of soluble angiotensin-converting enzyme 2 concentrations in adult patients with complex congenital heart disease33280062
  • Pattern of circulating SARS©\CoV©\2©\specific antibody©\secreting and memory B©\cell generation in patients with acute COVID©\1933552508
  • Novel transgenic mice with Cre-dependent co-expression of GFP and human ACE2: a safe tool for study of COVID-19 pathogenesis33855640
  • Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera
  • Immunoreactivity of the SARS-CoV-2 entry proteins ACE-2 and TMPRSS-2 in murine models of hormonal manipulation, ageing, and cardiac injury34907257
  • Angiotensin‐converting enzyme 2 and Transmembrane protease serine 2 in female and male patients with end‐stage kidney diseasePubmed:35366343
  • Ramipril Reduces Acylcarnitines and Distinctly Increases Angiotensin-Converting Enzyme 2 Expression in Lungs of RatsPubmed:35448480

Recommend products